Daratumumab subcutaneous, first approved treatment for newly diagnosed AL amyloidosis in EuropeAccess, AL amyloidosis23 June 2021
Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregiversAL amyloidosis, MPE, Myeloma, Patient evidence21 June 2021
Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosisAccess, AL amyloidosis17 January 2021
Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlightsAL amyloidosis, Conferences, MPE, Myeloma, Videos18 December 2020
ASH 2020 | Data on Real World Evidence (RWE) on AL amyloidosisAL amyloidosis, Conferences10 December 2020
MPE webinar on ASH 2020 myeloma and AL amyloidosis highlightsAL amyloidosis, MPE, Myeloma8 December 2020
ASH 2020 | Certain people with blood cancers and COVID-19 infection vulnerable to severe illnessAL amyloidosis, Conferences, Myeloma6 December 2020
